Pharmaceuticals News & Press Release Distribution

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8 a.m. EST on...

2022-05-19 20:00 2479

Berry Oncology Launches an Innovative Self-Iterative "HIFI" System

BEIJING, May 18, 2022 /PRNewswire/ -- Berry Oncology, a leading company in the global industry for genetic testing and early screening of tumors, recently launched a HIFI system. The HIFI system consists of HIFI-det liquid biopsy technology and the corresponding HIFI-cal series of algorithms. W...

2022-05-19 09:00 3183

PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding

BOSTON, May 19, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The cente...

2022-05-19 04:56 4997

Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine

SUZHOU, China and ROCKVILLE, Md., May 18, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a new preclinical study, conducted by the rese...

2022-05-18 22:06 3144

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

VANCOUVER, BC, May 18, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils deLyon, France ("HCL") has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company's autologous ...

2022-05-18 20:00 5190

Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

SHANGHAI and HONG KONG, May 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2022-05-18 15:01 4055

SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

HONG KONG, May 18, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096) announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute ofMateria Medica (SIMM) and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the Clinica...

2022-05-18 11:56 2954

SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

Sinclair Pharma Partners with Vanguard Aesthetics to Launch Silhouette Soft in Malaysia

Equipped with the world's only cone technology for optimal lift, Silhouette Soft provides longer lasting results. KUALA LUMPUR, Malaysia, May 18, 2022 /PRNewswire/ -- Sinclair Pharma , a global pharmaceutical brand providing aesthetic dermatology and collagen solutions is ...

2022-05-18 09:01 4814

ASEAN accepts mutually recognized COVID-19 vaccination certificates

DENPASAR, Indonesia, May 17, 2022 /PRNewswire/ -- ASEAN Member States collectively recognize the COVID-19 vaccination certificate to be applied in Southeast Asia. Health Ministers of ASEAN countries endorsed the decision during the 15th ASEAN Health Ministers Meeting (15th AHMM) inNusa Dua, Bali, ...

2022-05-17 19:14 3042

ASEAN accepts mutually recognized COVID-19 vaccination certificates

ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY

PARIS, May 17, 2022 /PRNewswire/ -- ABL Europe (ABL ), a pure play contract development and manufacturing organization (CDMO) specialized in development and manufacturing of virus for vaccine candidates, gene and cancer therapies and Odimma Therapeutics (Od...

2022-05-17 15:00 4083

CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interim analysis

* Sugemalimab is the world's first anti-PD-(L)1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression following concurrent or sequential chemoradiotherapy * The National Medical Pr...

2022-05-17 08:02 4171

Ascletis (1672.HK) Included in MSCI China Small Cap Index

HANGZHOU and SHAOXING, China, May 16, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the MSCI China Small Cap Index, effective after the market close onMay 31, 2022. Morgan Stanley Capital International (MSCI) is a leading provider o...

2022-05-16 20:17 5525

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

-Distribution channels in place to streamline/facilitate patient access. -XPOVIO® will be available in 600 hospitals and 105 DTPs (across China includingBeijing, Shanghai, Guangdong, Jiangsu, Zhejiang, Henan, and Shandong). SHANGHAI and HONG KONG, May 16, 2022 /PRNewswire/ -- Antengene Corporatio...

2022-05-16 11:20 4186

GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

SUZHOU, China, May 15, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter referred to as "GeneQuantum"), a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won...

2022-05-16 09:00 2952

Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, May 16, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...

2022-05-16 08:00 4670

Kintor Pharma Included in MSCI China Index

SUZHOU, China, May 15, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced today that the company's stock has been included in the MSCI China Index, e...

2022-05-15 18:28 4383

Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting

SHANGHAI, May 13, 2022 /PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T cell lymphoma (r/r PTCL) in oral session at the 27th European Hematology Association 2022 (EHA2022)...

2022-05-13 19:09 3411

Seegene reports first quarter 2022 financial results

* Q1 revenue up 10% QoQ to reach record quarterly high of KRW 451.5 billion * Foundation for sales expansion strengthened through '3 Ct' technology commercialization, Allplex™ RV Master Assay approval, increased PCR instrument sales * "Seegene to secure future growth by targeting syndromic t...

2022-05-13 19:00 3433

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2022-05-13 18:00 4105

Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2022-05-13 08:30 3719